

Additional data file 15A. DNAm signature in primary Carboplatin-treated “INNSBRUCK” ovarian cancer set (n=63). Cox-regression Hazard ratio (with 95% confidence intervals), likelihood ratio test P-value, and number of data values, for various predictive factors in the subset of 63 Carboplatin treated ovarian cancer patients, using the full follow-up period (maximum 17 years) and for the case of a 5 year observation window (all events censored at 5 years). *HOTAIR*-DNAm-multivariate denotes multivariate analysis adjusted for age, stage and size of residual tumor.

[†] *HOTAIR* DNAm correlation score was used (not the binarised score).

[§] *HOTAIR* DNAm correlation score was binarised into high and low groups according to a cut-off value as described in Supplementary Methods.

Factor	Full period			<5 yrs		
	HR (95%CI)	P	n	HR (95%CI)	P	n
Age	1.51 (1.11-2.05)	0.008	63	1.70 (1.18-2.47)	0.003	63
Stage	1.88 (1.28-2.77)	0.001	63	1.88 (1.20-2.96)	0.005	63
Grade	1.39 (0.79-2.46)	0.25	59	1.01 (0.53-1.93)	0.98	59
Residual Tumor	3.06 (1.90-4.93)	<0.001	60	3.18 (1.85-5.46)	<0.001	60
<i>HOTAIR</i> -DNAm [†]	1.56 (1.18-2.07)	0.001	63	1.76 (1.27-2.45)	<0.001	63
<i>HOTAIR</i> -DNAm [§]	2.34 (1.29-4.26)	0.004	63	3.07 (1.49-6.31)	0.001	63
<i>HOTAIR</i> -DNAm [†] multivariate	1.54 (1.09-2.17)	0.01	60	1.72 (1.14-2.59)	0.009	60
<i>HOTAIR</i> -DNAm [§] multivariate	2.35 (1.19-4.63)	0.01	60	2.76 (1.24-6.18)	0.01	60

Additional data file 15B. DNAm signature in the independent “TCGA” set (n=316; Carboplatin based treatment; excluding Cisplatin treated patients). Cox-regression Hazard ratio (with 95% confidence intervals), likelihood ratio test P-value, and number of data values, for various predictive factors in the TCGA set, using the full follow-up period (maximum 10.8 years) and for the case of maximum 5 years follow-up period (all observations after 5 years are censored at 5 years). *HOTAIR*-DNAm-multivariate denotes multivariate analysis adjusted for age, stage and size of residual tumor (full period) and for age, stage, grade and size of residual tumor for 5 year observation window. All Cox-regressions were stratified by the medical health center the patients came from to account for inter-center differences in survival distributions.

† *HOTAIR* DNAm correlation score was used (not the binarised score).

§ *HOTAIR* DNAm correlation score was binarised into high and low groups according to a cut-off value as described in Supplementary Methods.

Factor	Full period			<5 yrs		
	HR (95%CI)	P	n	HR (95%CI)	P	n
Age	1.20 (1.00-1.43)	0.05	275	1.27 (1.05-1.53)	0.01	275
Stage	1.70 (1.12-2.56)	0.012	275	1.54 (1.00-2.38)	0.05	275
Grade	1.23 (0.71-2.12)	0.46	268	1.65 (0.87-3.10)	0.12	268
Residual Tumor	1.39 (0.98-1.96)	0.062	246	1.29 (0.91-1.85)	0.16	246
<i>HOTAIR</i> -DNAm [†]	1.44 (1.19-1.73)	<0.001	275	1.55 (1.27-1.88)	<0.00001	275
<i>HOTAIR</i> -DNAm [§]	1.49 (1.07-2.10)	0.02	275	1.77 (1.22-2.58)	0.003	275
<i>HOTAIR</i> -DNAm [†] multivariate	1.32 (1.07-1.61)	0.01	246	1.45 (1.17-1.80)	<0.001	241
<i>HOTAIR</i> -DNAm [§] multivariate	1.68 (1.10-2.56)	0.02	241	1.91 (1.23-2.98)	0.004	241